Comparison of ceftazidime-avibactam susceptibility testing methods against OXA-48-like carrying Klebsiella blood stream isolates.
| Autor: | Isler B; University of Queensland, Faculty of Medicine, UQ Centre for Clinical Research, Brisbane, Australia; Infection Management Services, Princess Alexandra Hospital, Brisbane, Australia. Electronic address: burcu.isler@uq.edu.au., Vatansever C; Infectious Diseases and Clinical Microbiology, School of Medicine, Koç University, Istanbul, Turkey., Özer B; Infectious Diseases and Clinical Microbiology, School of Medicine, Koç University, Istanbul, Turkey., Çınar G; Infectious Diseases and Clinical Microbiology, Ankara University School of Medicine, Ankara, Turkey., Aslan AT; Infectious Diseases and Clinical Microbiology, Hacettepe University School of Medicine, Ankara, Turkey., Stewart A; University of Queensland, Faculty of Medicine, UQ Centre for Clinical Research, Brisbane, Australia., Simos P; Infection Management Services, Princess Alexandra Hospital, Brisbane, Australia., Falconer C; University of Queensland, Faculty of Medicine, UQ Centre for Clinical Research, Brisbane, Australia., Bauer MJ; University of Queensland, Faculty of Medicine, UQ Centre for Clinical Research, Brisbane, Australia., Forde B; University of Queensland, Faculty of Medicine, UQ Centre for Clinical Research, Brisbane, Australia., Harris P; University of Queensland, Faculty of Medicine, UQ Centre for Clinical Research, Brisbane, Australia., Şimşek F; Infectious Diseases and Clinical Microbiology, University of Health Sciences, Ministry of Health Prof Dr Cemil Taşçıoğlu City Hospital, Istanbul, Turkey., Tülek N; Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Atilim University, Ankara, Turkey., Demirkaya H; Infectious Diseases and Clinical Microbiology, Başkent University, Ankara Hospital, Ankara, Turkey., Menekşe Ş; Infectious Diseases, Koşuyolu Kartal Heart Training and Research Hospital, Istanbul, Turkey., Akalin H; Infectious Diseases and Clinical Microbiology, Uludağ University School of Medicine, Bursa, Turkey., Balkan İİ; Infectious Diseases and Clinical Microbiology, Istanbul University-Cerrahpaşa, School of Medicine, Istanbul, Turkey., Aydın M; Infectious Diseases and Clinical Microbiology, Ümraniye Training and Research Hospital, University of Health Sciences, Istanbul, Turkey., Tigen ET; Infectious Diseases and Clinical Microbiology, Marmara University, Pendik Training and Research Hospital, Istanbul, Turkey., Demir SK; Infectious Diseases and Clinical Microbiology, Demiroglu Bilim University, Istanbul, Turkey., Kapmaz M; Infectious Diseases and Clinical Microbiology, Koç University Hospital, Istanbul, Turkey., Keske Ş; Infectious Diseases and Clinical Microbiology, School of Medicine, Koç University, Istanbul, Turkey; Infectious Diseases, VKV American Hospital, Istanbul, Turkey., Doğan Ö; Infectious Diseases and Clinical Microbiology, School of Medicine, Koç University, Istanbul, Turkey., Arabacı Ç; Clinical Microbiology, University of Health Sciences, Ministry of Health Prof Dr Cemil Taşçıoğlu City Hospital, Istanbul, Turkey., Yağcı S; Clinical Microbiology, Ankara Training and Research Hospital, Ankara, Turkey., Hazırolan G; Clinical Microbiology, Hacettepe University School of Medicine, Ankara, Turkey., Bakır VO; Graduate School of Sciences and Engineering, Koç University, Istanbul, Turkey., Gönen M; Industrial Engineering, College of Engineering, Koç University, Istanbul, Turkey., Saltoğlu N; Infectious Diseases and Clinical Microbiology, Istanbul University-Cerrahpaşa, School of Medicine, Istanbul, Turkey., Azap A; Infectious Diseases and Clinical Microbiology, Ankara University School of Medicine, Ankara, Turkey., Azap Ö; Infectious Diseases and Clinical Microbiology, Başkent University, Ankara Hospital, Ankara, Turkey., Akova M; Infectious Diseases and Clinical Microbiology, Hacettepe University School of Medicine, Ankara, Turkey., Ergönül Ö; Infectious Diseases and Clinical Microbiology, School of Medicine, Koç University, Istanbul, Turkey; Koç University İş Bank Centre for Infectious Diseases (KUISCID), Istanbul, Turkey., Paterson DL; University of Queensland, Faculty of Medicine, UQ Centre for Clinical Research, Brisbane, Australia., Can F; Infectious Diseases and Clinical Microbiology, School of Medicine, Koç University, Istanbul, Turkey; Koç University İş Bank Centre for Infectious Diseases (KUISCID), Istanbul, Turkey. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Diagnostic microbiology and infectious disease [Diagn Microbiol Infect Dis] 2022 Sep; Vol. 104 (1), pp. 115745. Date of Electronic Publication: 2022 Jun 18. |
| DOI: | 10.1016/j.diagmicrobio.2022.115745 |
| Abstrakt: | Ceftazidime-avibactam exhibits good in vitro activity against carbapenem resistant Klebsiella carrying OXA-48-like enzymes. We tested two hundred unique carbapenem resistant Klebsiella blood stream isolates (71% with single OXA-48-like carbapenemases, including OXA-48, n = 62; OXA-232, n = 57; OXA-244, n = 17; OXA-181, n = 5) that were collected as part of a multicentre study against ceftazidime-avibactam using Etest (bioMérieux, Marcyl'Étoile, France), 10/4 μg disc (Thermo Fisher) and Sensititre Gram Negative EURGNCOL Plates (Lyophilized panels, Sensititre, Thermo Fisher) with the aim of comparing the performances of the Etest and disc to that of Sensititre. Ceftazidime-avibactam MIC Competing Interests: Declaration of competing interest Dr. Paterson reports research grants from Merck, Pfizer and Shionogi. David Paterson has received honoraria for advisory board membership from Merck, Pfizer, Shionogi, GSK, QPex, Entasis, VenatoRx, BioMerieux, and Accelerate. Dr Harris has received research grants from Sandoz, Merck/MSD and Shionogi, speaker's fees from Pfizer and honoraria for advisory board membership from Merck and Sandoz, paid to the University of Queensland. All others have no conflict of interest to declare. (Copyright © 2022 Elsevier Inc. All rights reserved.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|
Full Text from ScienceDirect